Efficacy and safety of total parathyroidectomy with autotransplantation vs. subtotal parathyroidectomy for secondary hyperparathyroidism: a retrospective study

Efficacy and safety of total parathyroidectomy with autotransplantation vs. subtotal parathyroidectomy for secondary hyperparathyroidism: a retrospective study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Efficacy and safety of total parathyroidectomy with autotransplantation vs. subtotal parathyroidectomy for secondary hyperparathyroidism: a retrospective study Jiaqi Zhu, Yan Wu, Ting Huang, Guoqin Jiang, Zhixue Yang This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1363603/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background : No consensus has been reached on the best surgical approach for secondary hyperparathyroidism. We evaluated the short-term and long-term efficacy and safety of total parathyroidectomy with autotransplantation (TPTX+AT) and subtotal parathyroidectomy (SPTX). Methods : We retrospectively analyzed the data of 259 patients undergoing TPTX+AT or SPTX between 2010 and 2021 in the Second Affiliated Hospital of Soochow University, and carried out follow-up. We compared the differences in symptoms, serological examinations, complications and mortalities between the two groups, and explored the risk factors of poor prognosis, death and recurrence. Results : Of the 259 patients, 208 underwent TPTX+AT and 51 underwent SPTX. The postoperative day 1 serum intact PTH level was higher in TPTX+AT group than that in SPTX group (P=.023). The risk of all-cause mortality in TPTX+AT group was lower (P =. 018), and recurrent PTX was more common in TPTX+AT group (P =. 011). The risk of recurrence was similar. There was no significant difference in the incidence of most complications including hematoma, recurrent laryngeal nerve injury, wound infection, adverse cardiovascular outcomes, fracture and permanent hypoparathyroidism between two groups. Results from Cox regression showed the SPTX operation approach (HR 3.53, P = 0.021) and older age (HR 1.06, P = 0.035) were risk factors of all-cause mortality. Conclusion : Due to the lower risk of death after TPTX+AT and the low renal transplantation rate, we prefer TPTX+AT to treat most Chinese population with secondary hyperparathyroidism. efficacy secondary hyperparathyroidism total parathyroidectomy with autotransplantation subtotal parathyroidectomy end-stage renal disease Figures Figure 1 Figure 2 Figure 3 Introduction Secondary hyperparathyroidism (SHPT) is a common complication of chronic renal failure. It exists in almost all patients with end-stage renal disease (ESRD), mainly caused by the metabolic disorder of calcium, phosphorus and vitamin D [ 1 ]. The most obvious feature of SHPT is the elevated level of parathyroid hormone (PTH). Patients suffer from symptoms of bone and joint pain, pruritus, fatigue, insomnia, constipation [ 2 , 3 ]. In more severe cases, pathological fractures, cardiovascular complications and death may occur [ 4 , 5 ]. In addition, high levels of serum intact parathyroid hormone (iPTH), calcium and phosphorus are considered to be associated with an increased risk of death. All these can be improved by treating SHPT [ 6 ].SHPT is mainly treated with pharmaceutical therapies and surgery, and microwave ablation also has a certain effect [ 7 , 8 ]. The pharmaceutical therapies contain Vitamin D therapy, calcimimetics and phosphorus binders. Those who are unresponsive to drugs should consider parathyroidectomy (PTX) [ 1 , 9 ]. With the use of cinacalcet and paricalcitol, more patients are able to control PTH levels. However, the rate of PTX did not therefore show a long-term decline accompanied with these therapeutic progress and parathyroidectomy is still an important treatment for SHPT [ 10 ]. About 38% of patients need PTX after 20 years’ dialysis [ 11 ]. There are three main approaches of PTX, namely subtotal parathyroidectomy (SPTX), total parathyroidectomy with autotransplantation (TPTX + AT) and total parathyroidectomy (TPTX), of which the former two are the most common [ 12 – 14 ]. Some scholars have also proposed other methods that are more conservative or more radical than these three traditional ones, depending on the goal of PTH control [ 15 , 16 ]. Which way is the best is still in controversy [ 17 , 18 ]. SPTX is more common in Europe and the United States, while TPTX + AT is conducted more frequently in Asian countries, which may be attributed to the difference of renal transplantation rate [ 1 , 19 ]. A meta-analysis published in 2019 concluded that there is no significant difference in recurrence rate, complication rate and mortality between TPTX + AT and SPTX [ 18 ]. Polina V Zmijewski et al [ 20 ] found that TPTX + AT has the advantage of lower recurrence rate when compared with SPTX, but the incidence of long-term hypocalcemia was higher. The risk of permanent hypoparathyroidism after SPTX is relatively lower, while TPTX + AT has the advantage of avoiding another neck surgery [ 18 ].Due to the differences in sample size, follow-up time and measurement, previous studies on these two surgical methods did not reach a consensus. The effects of postoperative level of PTH and calcium on cardiovascular complications and mortality need to be further evaluated. The aim of our study is therefore to compare the efficacy and safety of SPTX and TPTX + AT in short and long time from multiple perspectives. Methods Subjects After the approval of the Review Board of the Second Affiliated Hospital of Soochow University, we collected the data of patients diagnosed as SHPT and undergoing parathyroidectomy from January 1, 2010 to January 31, 2021. The inclusion criteria included: ESRD patients on hemodialysis or peritoneal dialysis; diagnosed as SHPT by symptoms, signs, and serologic and imaging examination; operative approach was TPTX+AT or SPTX; all relating data were complete. We excluded those who had received renal transplantation before PTX. Finally, a total of 259 patients were included in this study. Before operation, all patients or their relatives signed informed consent forms to participate in the study. All procedures were in accordance with the relevant guidelines and regulations. Perioperative procedure Indications for PTX included persistently elevated iPTH level >800 pg/ml for more than 6 months that pharmaceutical therapies became ineffective, or there were significant symptoms [1, 20, 21]. All patients were examined with parathyroid ultrasound and 99mTc-sestamibi radionuclide scan (Fig. 1). Serum iPTH, calcium and phosphorus were routinely evaluated before operation and in the early morning of the first day after operation. In TPTX+AT, all parathyroid glands were removed, and part of one approximately normal parathyroid was sliced into pieces at size of 1mm 3 , then 12~20 pieces were evenly transplanted in brachioradialis muscle in which side dialysis fistula was not located. Or parathyroid tissue can be directly made into homogenate and injected into deltoid muscle through syringe (Fig. 2). In SPTX, we retained about 50mg of the smallest parathyroid gland with all the remaining glands removed. Routine neck ultrasonography usually helps find thyroid lesions accidentally. Taking the complexity of reoperation on neck into consideration, we aggressively performed unilateral or bilateral thyroidectomy for those who are at great risk of thyroid cancer, with lymph node dissection carried out when necessary. After handling all parathyroid glands, intraoperative iPTH level and frozen pathological examination were used in most patients in order to improve the success rate of the operation. If the level of intraoperative iPTH failed to drop below 50% of the preoperative level, we would search for the residual parathyroid gland, then examine iPTH again. All patients were treated with large doses of oral calcium, vitamin D3 or calcitriol, and intravenous calcium gluconate to prevent severe hypocalcemia, which was defined as serum calcium less than 1.6 mmol/L in any examination postoperatively. Serum calcium and phosphorus level were monitored every 6 hours within 24 hours after surgery. The frequency of monitoring and the dose of calcium supplement were adjusted according to the calcium level. When serum calcium When serum calcium rose to >1.9 mmol/L, with no symptoms of hypocalcemia like numbness and limb cramp, intravenous calcium was stopped to given. Patients on hemodialysis underwent dialysis on the day before and after surgery, while patients on peritoneal dialysis continued to dialysis on the night of surgery. Changes of patients’ symptoms were evaluated within 7 days after operation. Perioperative complications, such as cervical hematoma, recurrent laryngeal nerve injury and infection, were recorded. Most patients were discharged after cervical drainage tube was removed and serum calcium reached a stable level. A few patients left hospital before that and immediately went to their dialysis center for further treatment. Follow-up All patients enrolled in the study were given a phone call for follow-up, which was conducted by the same doctor. The follow-up was accomplished with the assistance of patients and/or their close relatives who had a full comprehension of their own condition. We collected data of all-cause mortality, recurrence, reoperation, adverse cardiovascular outcomes, and the corresponding time. We also recorded other complications such as fracture and permanent hypoparathyroidism, the relapse of common symptoms, and indicators which can reflect the economic burden of patients, including long-term pharmaceutical therapies and renal transplantation. Since some patients’ dialysis center were not in our hospital, results of their postoperative serological examination cannot be directly obtained. For those who lack objective data, we got the missing data from the call. In our study, adverse cardiovascular outcomes were defined as angina pectoris, myocardial infarction, stroke, aneurysm rupture, and limb ischemia. We defined persistent SHPT as elevated iPTH >300pg/ml in any monitoring within 7 days after operation, and recurrent SHPT as iPTH increased >300pg/ml again during follow-up after a successful decrease postoperatively. It should be noted that the definitions of persistent and recurrent disease vary between literatures [13, 20-24]. Statistical analysis SPSS 23.0 and GraphPad Prism 5.01 were used for statistical analysis. Continuous variables are shown with means and standard deviations if they approximately conform to normal distribution, otherwise they are displayed by medians and interquartile ranges. Categorical variables are presented in numbers and percentages. Independent samples t test, chi-square test, Fisher’s exact test and Wilcoxon signed rank test were used to compare differences between the two groups depending on the type of variables when appropriate. Binary logistic regression analysis was used to look for risk factors for persistent SHPT. Kaplan-Meier method was utilized to show the incidence of all-cause death, recurrent SHPT, recurrent PTX (re-PTX) and adverse cardiovascular outcomes, and the differences between two groups were analyzed by stratified log-rank test. Risk factors for all-cause mortality and recurrent SHPT were evaluated by Cox-proportional hazard regression model. Covariates included gender, age, combined chronic diseases including hypertension, diabetes and coronary heart disease (others were not included because of the low quantity), level of preoperative serological examination, surgical method, number of parathyroid glands identified in operation and pathological results. P value was calculated by Wald test. Univariate Cox regression analysis was carried out for each covariate, then those with P<.05 were further enrolled into the multivariate analysis to determine the final risk factors. In all analyses, P<0.05 was considered statistically significant. Results Baseline characteristics of the SPTX and TPTX+AT groups There was no statistical difference in gender, age, serum calcium and phosphorus level, common symptoms (orthopedic pain, pruritus, obvious fatigue) and combined chronic diseases (hypertension, diabetes, coronary heart disease, stroke) between the SPTX and TPTX+AT groups (all P>.05). Preoperative serum iPTH and ALP level was higher in SPTX group than that in TPTX+AT group (P<.05). Due to the change of the preference of our medical team, no patient underwent SPTX in this study(P<.05) (Table 1). Table 1 Some baseline characteristics of patients undergoing parathyroidectomy TPTX+AT(n=208) SPTX(n=51) P value Female sex 96 (46.2) 28 (54.9) 0.262 Age, y 50.3 (11.9) 49.0 (10.4) 0.479 Number of parathyroid glands found by ultrasound 3.04 (0.94) 3.43 (0.70) 0.006 Number of hyperfunctional parathyroid glands found by MIBI 3.14 (1.03) 2.67 (1.09) 0.004 Orthopedic pain 0.114 Severe 55 (26.4) 18 (35.3) Light 78 (37.5) 20 (39.2) Pruritus 148 (71.2) 34 (66.7) 0.530 Obvious fatigue 35 (16.8) 7 (13.7) 0.590 Hypertension 159 (76.4) 41 (80.4) 0.530 Diabetes 20 (9.6) 5 (9.8) 0.967 Coronary heart disease 14 (6.7) 2 (3.9) 0.673 Stroke 7 (3.4) 0 (0) 0.397 iPTH, pg/mL 1577.4 (1152.9-2177.8) 1835.5 (1275.4-2621.0) 0.023 Serum calcium, mmol/L 2.53 (0.23) 2.52 (0.23) 0.934 Serum phosphorus, mmol/L 2.29 (0.47) 2.31 (0.52) 0.838 ALP, U/L 254.5 (137.3-437.8) 488.0 (193.0-825.0) <0.001 Year of parathyroidectomy <0.001 ≤2013 11 (5.3) 12 (23.5) 2014-2017 72 (34.6) 39 (76.5) ≥2018 125 (60.1) 0 (0) Values are numbers (percent), mean (standard deviation) or median (interquartile range). TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; MIBI： 99m Tc-sestamibi radionuclide scan; IQR: interquartile range; iPTH: intact parathyroid hormone; ALP: alkaline phosphatase. Surgical results of the SPTX and TPTX+AT groups The number of parathyroid glands identified during operation between the two groups had no statistical difference (P=.120). More patients in TPTX+AT group underwent thyroidectomy concurrently than SPTX group (P=.006). The operation time in TPTX+AT group was statistically longer than SPTX group (both P<.05). Additional thyroidectomy would increase operation time, as a result, when patients who underwent thyroidectomy were excluded, the difference in operation time became no longer statistically significant (TPTX+AT: 125.4±38.8min, SPTX: 117.0±27.4min, P=.096). There are more patients diagnosed as parathyroid adenoma in TPTX+AT group than SPTX group (P<.05). Short-term efficacy and complications of the SPTX and TPTX+AT groups On postoperative day 1 (POD1), the levels of serum iPTH, calcium and phosphorus decreased significantly compared with those before operation (all P<.05). The level of iPTH was significantly higher than that in TPTX+AT group (P=.023). The POD1 serum calcium level is higher in TPTX+AT group than that in SPTX group (P=.012), however, this difference was not statistically significant by 7 days after operation (P=.355). The results of laboratory examination on POD7 were lacked because they were discharged at that time. The rate of persistent SHPT in SPTX group is statistically higher than that in TPTX+AT group (P=.020). Further binary logistic regression analysis showed that high level of preoperative ALP (OR 1.002, 95% CI 1.000-1.004, P=.036) and small number of parathyroid glands identified during operation (OR 0.046, 95% CI 0.006-0.379, P=.004) were the risk factors for persistent disease. In terms of complications, severe hypocalcemia (TPTX+AT: 23.6%, SPTX: 19.6%, P=.547) was the most common. The incidence of cervical hematoma, wound infection and recurrent laryngeal nerve injury was very low, and there was no statistical difference between the two groups (all P>.05). No patient died during postoperative inpatient period. One patient who underwent TPTX+AT had blockage of lower limb dialysis fistula, resulting in local and systemic infection. The postoperative inpatient days was longer in SPTX group (P<.001) (Table 2). Common symptoms of most patients were improved after operation, and no statistical difference was found between the two groups (all P<.05) (Table 3). Table 2 Perioperative information of patients undergoing parathyroidectomy TPTX+AT(n=208) SPTX(n=51) P value Operation time, min 128.3 (38.8) 116.2 (27.0) 0.010 Number of parathyroid glands identified 3.93 (0.38) 3.80 (0.53) 0.120 Thyroidectomy performed concurrently 47 (22.6) 3 (5.9) 0.006 Pathological result 0.041 Hyperplasia 205 (98.6) 47 (92.2) Adenoma 3 (1.4) 4 (7.8) Diagnosed as thyroid carcinoma 14 (6.7) 0 (0) 0.119 POD1 iPTH, mmol/L 9.7 (5.4-24.2) 37.1 (7.0-121.8) 0.023 POD1 calcium, mmol/L 1.91 (0.28) 1.81 (0.23) 0.012 POD1 phosphorus, mmol/L 1.83 (0.53) 1.84 (0.53) 0.913 POD7 calcium, mmol/L (n=180) 1.86 (0.25) 1.90 (0.19) 0.355 POD7 phosphorus, mmol/L (n=180) 1.13 (0.38) 1.18 (0.53) 0.581 Persistent SHPT 4 (1.9) 5 (9.8) 0.020 Severe hypocalcemia 49 (23.6) 10 (19.6) 0.547 Hematoma 2 (1.0) 1 (2.0) 0.484 Recurrent laryngeal nerve injury 1 (0.5) 1 (2.0) 0.356 Wound infection 0 (0) 0 (0) 1.000 Postoperative inpatient days, d 7.32 (5.20) 10.29 (5.83) <0.001 Values are numbers (percent) or mean (standard deviation). PTX: parathyroidectomy; TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; IQR:interquartile range; iPTH: intact parathyroid hormone; POD: postoperative day; SHPT: secondary hyperparathyroidism. Table 3 Changes of common symptoms in patients undergoing parathyroidectomy Postoperative Symptoms Group Preoperative Completely improved Partly improved Barely changed Orthopedic pain Severe TPTX+AT 55 (26.4) 43 (78.2) 8 (14.5) 4 (7.3) SPTX* 18 (35.3) 12 (66.7) 5 (27.8) 1 (5.6) Light TPTX+AT 78 (37.5) 61 (78.2) 6 (7.7) 11 (14.1) SPTX* 20 (30.2) 14 (70.0) 2 (10.0) 4 (20.0) Pruritus TPTX+AT 148 (71.2) 85 (57.4) 31 (20.9) 32 (21.6) SPTX* 34 (66.7) 21 (61.8) 8 (23.5) 5 (14.7) Obvious fatigue TPTX+AT 35 (16.8) 13 (37.1) 10 (28.6) 12 (34.3) SPTX* 7 (13.7) 5 (71.4) 1 (14.3) 1 (14.3) Values are numbers (percent). *P>.05 compared with TPTX+AT group postoperativelly TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy Follow-up results and long-term outcomes of the SPTX and TPTX+AT groups After follow-up of all patients included in this study, we excluded 45 patients who were missed follow-up due to telephone change, inability to connect, reluctance to collaborate, and unclear memory. The remaining 204 patients included 165 in TPTX+AT group and 39 in SPTX group. The all-cause mortality in SPTX group is significantly higher than that in TPTX+AT group (P<.001). The causes of death included heart failure (4 cases), electrolyte disorder (4 cases), intracerebral hemorrhage (3 cases), malignant tumor (2 cases), myocardial infarction (1 case), infection (1 case) and accident (1 case). Recurrent SHPT happened in 29.7% of patients in SPTX group and 12.3% of patients in TPTX+AT group (P=.013). But conversely, re-PTX was less common in SPTX group (2.6%) than that in TPTX+AT group (9.1%), though not statistically significant (P=.302). There was no statistical difference between the two groups in complications like adverse cardiovascular outcomes, fracture, hypercalcemia, and permanent hypoparathyroidism. The two groups were similar in symptom deterioration, renal transplantation, and long-term pharmacal therapies (all P>.05) (Table 4, 5). Kaplan-Meier are shown in Fig. 3. Log rank test indicated TPTX+AT group has lower risk in all-cause death than SPTX group(P=.018), and re-PTX was more common in TPTX+AT group than that in SPTX group (P=.011). However, there was no statistical difference in recurrence and adverse cardiovascular outcomes between the two groups (both P>.05). Table 4 Long-term outcomes of patients undergoing parathyroidectomy TPTX+AT(n=165) SPTX(n=39) P value All-cause mortality 7 (4.2) 9 (23.1) <0.001 Recurrent SHPT* 20 (12.3) 11 (29.7) 0.013 Re-PTX 15 (9.1) 1 (2.6) 0.302 Adverse cardiovascular outcomes 11 (6.7) 4 (10.3) 0.666 Fracture 3 (1.8) 2 (5.1) 0.244 Prevalent hypercalcemia 13 (7.9) 2 (5.1) 0.802 Permanent hypoparathyroidism 9 (5.5) 0 (0) 0.290 Orthopedic pain worsened 8 (4.8) 2 (5.1) 1.000 Pruritus worsened 7 (4.2) 0 (0) 0.412 Renal transplantation 2 (1.2) 1 (2.6) 0.473 *Persistent SHPT were excluded. Values are numbers (percent). TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; SHPT: secondary hyperparathyroidism; Re-PTX: recurrent parathyroidectomy. Table 5 Long-term pharmaceutical therapies of patients undergoing parathyroidectomy TPTX+AT(n=165) SPTX(n=39) Pvalue Cinacalcet 17 (10.3) 2 (5.1) 0.488 Calcium 60 (36.4) 10 (25.6) 0.205 Vitamin D 53 (32.1) 9 (23.1) 0.269 Calcitriol 46 (27.9) 6 (15.4) 0.107 Phosphorus binders 54 (32.7) 15 (38.5) 0.496 Risk factors for all-cause death and recurrent SHPT Cox regression analysis was performed for all-cause death and recurrent SHPT, and the covariate stroke was not included for the number was too small. In individual variable Cox regression analysis, the SPTX operation approach, older age, lower level of preoperative serum phosphorus was found to be associated with all-cause death after operation (all P<.05). However, after multiple Cox regression analysis, only the SPTX operation approach (HR 3.53, 95%CI 1.12-10.32, P=.021) and older age (HR 1.06, 95%CI 1.00-1.12, P=.035) were considered as risk factors for all-cause death (Table 6). No risk factor for recurrent SHPT was found in individual variable Cox regression analysis (all P>.05). Table 6 Risk factors for all-cause death based on Cox regression analysis Variables Hazard Ratio 95% CI Pvalue Step 1: Individual variable analysis Operative approach TPTX+AT Comparison SPTX 3.29 1.17-9.25 0.024 Age at operation 1.06 1.01-1.12 0.018 Hypertension No Comparison Yes 3.67 0.48-27.77 0.209 Diabetes No Comparison Yes 3.47 0.92-13.00 0.064 Coronary heart disease No Comparison Yes 2.25 0.50-10.05 0.288 Preoperative iPTH 1.00 1.00-1.00 0.880 Preoperative serum calcium 1.39 0.15-12.82 0.772 Preoperative serum phosphorus 0.32 0.10-0.97 0.045 Preoperative ALP 1.00 1.00-1.00 0.060 Number of parathyroid glands identified 1.13 0.35-3.69 0.839 Pathological result Hyperplasia Comparison Adenoma Step 2: Multiple analysis Operative approach TPTX+AT Comparison SPTX 3.53 1.21-10.32 0.021 Age at operation 1.06 1.00-1.12 0.035 Preoperative serum phosphorus 0.60 0.21-1.70 0.338 CI: confidence interval; TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; iPTH: intact parathyroid hormone; ALP: alkaline phosphatase. Discussion In this retrospective study of parathyroidectomy, we evaluated two surgical approaches from both short-term and long-term perspectives, and nearly 80% of patients completed follow-up. We found that although TPTX + AT seemed to be more effective in treating SHPT than SPTX within a short period after operation, there was no significant difference between these two surgical methods in the recurrence after a long time. The proportion of re-PTX was higher in patients after TPTX + AT than after SPTX. The incidence of complications in the two groups was similar. Nevertheless, the all-cause mortality of SPTX group was significantly higher than that of TPTX + AT group (23.1% and 4.2% respectively). Heart failure is the main cause of death in both groups. TPTX + AT and SPTX are the two most common surgical treatments for SHPT, which can substantially improve patients’ symptoms and reduce mortality [ 22 ]. Which is the best surgical method is still controversial. Moreover, PTX is not without risk [ 1 ]. Our results showed that these two surgical approaches are both of great benefit to SHPT patients. Most patients could completely or partially improve their postoperative symptoms, and could show a significant decrease in the level of serum iPTH, calcium and phosphorus. However, binary logistic regression analysis showed that the small number of parathyroid glands detected during operation was a risk factor for permanent SHPT, while the surgical method was not, suggesting that the occurrence of permanent SHPT may be attributed to the failure to detect all parathyroid glands during operation, rather than a specific surgical approach. Severe hypocalcemia was happened more commonly in TPTX + AT group than in SPTX group. Although the difference was not statistically significant, it indicated some potential risks may existed. In this study, recurrent SHPT occurred in about 15% of the patients. We found that recurrent SHPT was not related to the surgical method. It should be noted that the rate of permanent hypoparathyroidism in TPTX + AT group was higher than that in SPTX group (5.5% vs 0%), although there was no statistical difference. These patients are being treated with calcium, vitamin D or calcitriol continuously. Some of them have had to be hospitalized for intravenous calcium supplement, which may increase the economic burden and nursing cost, but as far as we know, no serious event happened due to hypocalcemia. The KDIGO guideline also believes mild and asymptomatic hypocalcemia to be harmless [ 25 ]. Besides, only about 10% of patients need to take cinacalcet to inhibit the continuous increase of PTH after PTX, which means surgery can reduce the treatment cost of most patients. The proportion of re-PTX was higher in TPTX + AT group than that in SPTX group, which probably be closely correlated with the mode of reoperation, in that most reoperation after TPTX + AT could be carried out inpatient or outpatient under local anesthesia. However, in patients undergoing SPTX, the degradation of systemic organ function led by ESRD may make them unable to tolerate another general anesthesia operation a few years after the original operation. In addition, the acceptability of patients should be taken into account in the selection of surgical approach. Elin Isaksson et al conducted a retrospective analysis of 824 patients in Sweden who underwent SPTX or TPTX (whether combined with AT was not distinguished), and concluded that SPTX had a lower risk of cardiovascular events but similar mortality when compared with TPTX + AT. They also suspected that the occurrence of cardiovascular events was associated with excessively low levels of iPTH after TPTX + AT [ 26 ]. Our study obtained different results. The incidence of adverse cardiovascular outcomes was lower in both groups, and there was no significant difference between the two groups, while the risk of death was significantly higher in the SPTX group. From these results, TPTX + AT seems to be a safer approach. However, the major cause of mortality of our patients is heart failure, which is also the main cause of death of ESRD. Since ESRD, and the combined hypertension or diabetes can also induce cardiovascular diseases by multiple mechanisms [ 27 ], the relationship between operative methods and death still needs further study. Meanwhile, considering that only few patients (3/204) underwent renal transplantation after PTX, which is much lower than that study (273/804), it could possibly be reasons for the different results. We found that recurrent SHPT was not related to the surgical method. It should be noted that although the rate of permanent hypoparathyroidism in TPTX + AT group was higher than that in SPTX group (5.5% vs 0%), although there was no statistical difference. These patients are being treated with calcium, vitamin D or calcitriol continuously. Some of them have had to be hospitalized for intravenous calcium supplement, which may increase the economic burden and nursing cost, but as far as we know, no serious event happened due to hypocalcemia. The KDIGO guideline also believes mild and asymptomatic hypocalcemia to be harmless [ 25 ]. Besides, only about 10% of patients need to take cinacalcet to inhibit the continuous increase of PTH after PTX, which means surgery can reduce the treatment cost of most patients. Generally speaking, three and a half parathyroid glands are resected in SPTX, and TPTX + AT removes all parathyroid glands and then takes part of the tissue for autologous transplantation [ 1 , 24 ]. However, there are differences in detail. For instance, parathyroid autotransplantation can be occurred in sites like sternocleidomastoid muscle, subcutaneous abdominal adipose tissue, brachioradialis muscle, deltoid muscle and anterior tibial muscle [ 28 – 32 ]. In this study, the way of AT mainly depended on the preferences of surgeons, and was not distinguished. In recent years, more scholars have recommended TPTX alone for patients who have no hope of renal transplantation, and confirmed its safety and effectiveness, while TPTX + AT is still more recommended [ 14 , 17 , 22 ]. Out of concern about the complications of TPTX alone, our center has not widely carried out this approach. This study has some limitations. First, it is a retrospective study, lack of randomness. Second, there is imbalance in the follow-up time between the two groups. Though we have eliminated some of the effects through survival analysis, some information might still be missed. Third, the evaluation of patients' subjective feelings was mainly obtained by oral way, and no specific scale was used, which could lead to a certain bias. Conclusion TPTX + AT and SPTX are both effective surgical approaches for the treatment of SHPT. Effectiveness and complication rates of them are similar. Considering the potential lower mortality risk of TPTX + AT and the quite low renal transplantation rate in Chinese population, we prefer TPTX + AT to treat SHPT patients in most Chinese population. Abbreviations SHPT: secondary hyperparathyroidism; ESRD: end-stage renal disease; PTH: parathyroid hormone; iPTH: intact parathyroid hormone; PTX: parathyroidectomy; TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; re-PTX: recurrent PTX; POD: postoperative day; Declarations Ethics approval and consent to participate This study was approved by the Review Board of the Second Affiliated Hospital of Soochow University. All patients or their relatives signed informed consent forms to participate in the study. This study only collected the clinical data of patients and did not interfere with the treatment plan of patients. All patients’ privacy has been well protected. Consent for publication Not applicable. Availability of data and materials The datasets generated and/or analysed during the current study are not publicly available due the data collection process of this study took a large amount of time but are available from the corresponding author on reasonable request. Competing interests The authors declare that they have no competing interests Funding This study was supported by the preponderant clinic discipline lifting project funding of the Second Affiliated Hospital of Soochow University (XKTJ-XK202009). This was also partly supported by grants from maternal and child health research project of Jiangsu Province (F202036). The funder of XKTJ-XK202009 was mainly responsible for publication charges. The funder of F202036 was Zhixue Yang who participated in the design of the study, monitored its implement and was responsible for part of publication charges. Authors' contributions ZJQ interpreted the patient data of perioperative period, and was a major contributor in writing the manuscript. WY carried out follow-up and interpreted the corresponding data, and was a contributor in writing the manuscript. HT was responsible for statistical analysis. JGQ and YZX participated in the design of the study, and YZX monitored its implement and revised the manuscript. All authors read and approved the final manuscript. Acknowledgements We are deeply appreciative of the participants in this study and thank all staffs for their support and assistance. Authors' information 1 Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China. 2 Department of Emergency, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China. References Lau WL, Obi Y, Kalantar-Zadeh K: Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clinical journal of the American Society of Nephrology: CJASN 2018, 13(6):952–961. Filho WA, van der Plas WY, Brescia MDG, Nascimento CP, Jr., Goldenstein PT, Neto LMM, Arap SS, Custodio MR, Bueno RO, Moyses RMA et al: Quality of life after surgery in secondary hyperparathyroidism, comparing subtotal parathyroidectomy with total parathyroidectomy with immediate parathyroid autograft: Prospective randomized trial. Surgery 2018, 164(5):978–985. Levy AR, Xing S, Brunelli SM, Cooper K, Finkelstein FO, Germain MJ, Kimel M, Platt RW, Belozeroff V: Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study. American journal of kidney diseases: the official journal of the National Kidney Foundation 2020, 75(3):373–383. Demeure MJ, McGee DC, Wilkes W, Duh QY, Clark OH: Results of surgical treatment for hyperparathyroidism associated with renal disease. American journal of surgery 1990, 160(4):337–340. Konturek A, Barczyński M, Stopa M, Nowak W: Subtotal parathyroidectomy for secondary renal hyperparathyroidism: a 20-year surgical outcome study. Langenbeck's archives of surgery 2016, 401(7):965–974. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology: JASN 2004, 15(8):2208–2218. Diao Z, Liu X, Qian L, Liu J, Liu S, Liu W: Efficacy and its predictor in microwave ablation for severe secondary hyperparathyroidism in patients undergoing haemodialysis. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2016, 32(6):614–622. Zhao J, Qian L, Teng C, Yu M, Liu F, Liu Y, Tan X, Li J: A short-term non-randomized controlled study of ultrasound-guided microwave ablation and parathyroidectomy for secondary hyperparathyroidism. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2021, 38(1):1558–1565. Cozzolino M, Elli F, Carugo S, Ciceri P: Secondary Hyperparathyroidism in End-Stage Renal Disease: No Longer a Matter for Surgeons? Blood purification 2016, 42(1):44–48. Kim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM: Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. Clinical journal of the American Society of Nephrology: CJASN 2016, 11(7):1260–1267. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 2003, 42(4 Suppl 3):S1-201. Anderson K, Jr., Ruel E, Adam MA, Thomas S, Youngwirth L, Stang MT, Scheri RP, Roman SA, Sosa JA: Subtotal vs. total parathyroidectomy with autotransplantation for patients with renal hyperparathyroidism have similar outcomes. American journal of surgery 2017, 214(5):914–919. Liang Y, Sun Y, Ren L, Qi XW, Li Y, Zhang F: Short-term efficacy of surgical treatment of secondary hyperparathyroidism. European review for medical and pharmacological sciences 2015, 19(20):3904–3909. Polistena A, Sanguinetti A, Lucchini R, Galasse S, Avenia S, Monacelli M, Johnson LB, Jeppsson B, Avenia N: Surgical treatment of secondary hyperparathyroidism in elderly patients: an institutional experience. Aging clinical and experimental research 2017, 29(Suppl 1):23–28. Shan CX, Qiu NC, Zha SL, Liu ME, Wang Q, Zhu PP, Du ZP, Xia CY, Qiu M, Zhang W: A novel surgical strategy for secondary hyperparathyroidism: Purge parathyroidectomy. International journal of surgery (London, England) 2017, 43:112–118. Veyrat M, Fessi H, Haymann JP, Ronco P, Lacau St Guily J, Périé S: Conservative three-quarter versus subtotal seven-eighths parathyroidectomy in secondary hyperparathyroidism. European annals of otorhinolaryngology, head and neck diseases 2019, 136(2):63–68. Liu ME, Qiu NC, Zha SL, Du ZP, Wang YF, Wang Q, Chen Q, Cen XX, Jiang Y, Luo Q et al: To assess the effects of parathyroidectomy (TPTX versus TPTX + AT) for Secondary Hyperparathyroidism in chronic renal failure: A Systematic Review and Meta-Analysis. International journal of surgery (London, England) 2017, 44:353–362. Yuan Q, Liao Y, Zhou R, Liu J, Tang J, Wu G: Subtotal parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: an updated systematic review and meta-analysis. Langenbeck's archives of surgery 2019, 404(6):669–679. van der Plas W, Kruijff S, Sidhu SB, Delbridge LW, Sywak MS, Engelsman AF: Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease. Surgery 2021, 169(2):275–281. Zmijewski PV, Staloff JA, Wozniak MJ, Mazzaglia PJ: Subtotal Parathyroidectomy vs Total Parathyroidectomy with Autotransplantation for Secondary Hyperparathyroidism in Dialysis Patients: Short- and Long-Term Outcomes. Journal of the American College of Surgeons 2019, 228(6):831–838. Li JG, Xiao ZS, Hu XJ, Li Y, Zhang X, Zhang SZ, Shan AQ: Total parathyroidectomy with forearm auto-transplantation improves the quality of life and reduces the recurrence of secondary hyperparathyroidism in chronic kidney disease patients. Medicine 2017, 96(49):e9050. Schlosser K, Bartsch DK, Diener MK, Seiler CM, Bruckner T, Nies C, Meyer M, Neudecker J, Goretzki PE, Glockzin G et al: Total Parathyroidectomy With Routine Thymectomy and Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism: Results of a Nonconfirmatory Multicenter Prospective Randomized Controlled Pilot Trial. Annals of surgery 2016, 264(5):745–753. Choi HR, Aboueisha MA, Attia AS, Omar M, A EL, Toraih EA, Shama M, Chung WY, Jeong JJ, Kandil E: Outcomes of Subtotal Parathyroidectomy Versus Total Parathyroidectomy With Autotransplantation for Tertiary Hyperparathyroidism: Multi-institutional Study. Annals of surgery 2021, 274(4):674–679. Kim MS, Kim GH, Lee CH, Park JS, Lee JY, Tae K: Surgical Outcomes of Subtotal Parathyroidectomy for Renal Hyperparathyroidism. Clinical and experimental otorhinolaryngology 2020, 13(2):173–178. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND et al: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney international 2017, 92(1):26–36. Isaksson E, Ivarsson K, Akaberi S, Muth A, Prütz KG, Clyne N, Sterner G, Almquist M: Total versus subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery 2019, 165(1):142–150. Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A: Cardiovascular disease in dialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2018, 33(suppl_3):iii28-iii34. Casella C, Galani A, Totaro L, Ministrini S, Lai S, Dimko M, Portolani N: Total Parathyroidectomy with Subcutaneous Parathyroid Forearm Autotransplantation in the Treatment of Secondary Hyperparathyroidism: A Single-Center Experience. International journal of endocrinology 2018, 2018:6065720. Iorio O, Petrozza V, De Gori A, Bononi M, Porta N, De Toma G, Cavallaro G: Parathyroid Autotransplantation During thyroid Surgery. Where we are? A Systematic Review on Indications and Results. Journal of investigative surgery: the official journal of the Academy of Surgical Research 2019, 32(7):594–601. Tan CC, Cheah WK, Tan CT, Rauff A: Intramuscular injection of parathyroid autografts is a viable option after total parathyroidectomy. World journal of surgery 2010, 34(6):1332–1336. Anamaterou C, Lang M, Schimmack S, Rudofsky G, Büchler MW, Schmitz-Winnenthal H: Autotransplantation of parathyroid grafts into the tibialis anterior muscle after parathyroidectomy: a novel autotransplantation site. BMC surgery 2015, 15:113. Suwannasarn M, Jongjaroenprasert W, Chayangsu P, Suvikapakornkul R, Sriphrapradang C: Single measurement of intact parathyroid hormone after thyroidectomy can predict transient and permanent hypoparathyroidism: a prospective study. Asian journal of surgery 2017, 40(5):350–356. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1363603","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":84855487,"identity":"65b7d2ba-793d-4699-ae36-4bf5f35ea065","order_by":0,"name":"Jiaqi Zhu","email":"","orcid":"","institution":"The Second Affiliated Hospital of Soochow University","correspondingAuthor":false,"prefix":"","firstName":"Jiaqi","middleName":"","lastName":"Zhu","suffix":""},{"id":84855488,"identity":"71f062d0-5c4d-47a6-b824-204ee8c3e964","order_by":1,"name":"Yan Wu","email":"","orcid":"","institution":"The Second Affiliated Hospital of Soochow University","correspondingAuthor":false,"prefix":"","firstName":"Yan","middleName":"","lastName":"Wu","suffix":""},{"id":84855489,"identity":"b5471c1e-a618-4893-b55e-690ea34bbe0d","order_by":2,"name":"Ting Huang","email":"","orcid":"","institution":"The Second Affiliated Hospital of Soochow University","correspondingAuthor":false,"prefix":"","firstName":"Ting","middleName":"","lastName":"Huang","suffix":""},{"id":84855490,"identity":"d4313de9-228f-4334-a1c1-8a38c98fff54","order_by":3,"name":"Guoqin Jiang","email":"","orcid":"","institution":"The Second Affiliated Hospital of Soochow University","correspondingAuthor":false,"prefix":"","firstName":"Guoqin","middleName":"","lastName":"Jiang","suffix":""},{"id":84855491,"identity":"cd8118f6-269e-4ca8-925f-a2454e53b389","order_by":4,"name":"Zhixue Yang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAxUlEQVRIiWNgGAWjYJCCAxIV/+QYmEnQwfjA4swBY5K0MBtUth1IbCBavcGN9GcSN9vupM9v5z34gaHGJpqgFskZCWmSM849y91wmC9ZguFYWi5B6/glEo5JS5Qx525g5jGQYGw4TFgLm0Rim/QfNuZ0+WYe4x9EaeGXSGY2kGg7nMBwmMeMOFske54xPpA4k2a4AajFIoEYvxgcT38AjEobefn+M8Y3PtTYENbCIJCAxEnAoQgV8B8gStkoGAWjYBSMZAAApu4+cTbT/ZAAAAAASUVORK5CYII=","orcid":"","institution":"The Second Affiliated Hospital of Soochow University","correspondingAuthor":true,"prefix":"","firstName":"Zhixue","middleName":"","lastName":"Yang","suffix":""}],"badges":[],"createdAt":"2022-02-16 00:29:04","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1363603/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1363603/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":18488198,"identity":"4beff5d8-07e2-484d-a69a-d86fae8ab9e8","added_by":"auto","created_at":"2022-02-22 17:25:08","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":649298,"visible":true,"origin":"","legend":"\u003cp\u003eTypical imaging appearances of SHPT. (A) Four hyperfunctional parathyroid glands (the center of the cross) found by radionuclide imaging. (B) A huge parathyroid gland with a maximum diameter of about 4cm found by ultrasound.\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-1363603/v1/35c3f823733d31c9f02cd083.png"},{"id":18488199,"identity":"498b7c70-f145-4a13-9338-86af6f0116bf","added_by":"auto","created_at":"2022-02-22 17:25:08","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1029715,"visible":true,"origin":"","legend":"\u003cp\u003eIntraoperative findings and typical pathological appearances of SHPT. (A) Hyperplastic parathyroid glands found behind the thyroid (indicated by arrows). (B) Four completely resected parathyroid glands which were preserved in ice normal saline. (C) Microscopic appearances of parathyroid hyperplasia (left) and parathyroid adenoma (right).\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-1363603/v1/e5f8938f6ff8a89723238fa8.png"},{"id":18488197,"identity":"d8d6e9f6-cb4f-439e-9664-7438eeef0a1d","added_by":"auto","created_at":"2022-02-22 17:25:08","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":178050,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan-Meier curves of patients undergoing parathyroidectomy.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-1363603/v1/137f884e76d04eebde314108.png"},{"id":19182153,"identity":"5b766e80-9747-44ba-bd95-ab9efb923ca9","added_by":"auto","created_at":"2022-03-14 05:44:23","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1970732,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1363603/v1/f95c541c-ea78-480d-a660-ae260b3b4aeb.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Efficacy and safety of total parathyroidectomy with autotransplantation vs. subtotal parathyroidectomy for secondary hyperparathyroidism: a retrospective study","fulltext":[{"header":"Introduction","content":"\u003cp\u003eSecondary hyperparathyroidism (SHPT) is a common complication of chronic renal failure. It exists in almost all patients with end-stage renal disease (ESRD), mainly caused by the metabolic disorder of calcium, phosphorus and vitamin D [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. The most obvious feature of SHPT is the elevated level of parathyroid hormone (PTH). Patients suffer from symptoms of bone and joint pain, pruritus, fatigue, insomnia, constipation [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. In more severe cases, pathological fractures, cardiovascular complications and death may occur [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. In addition, high levels of serum intact parathyroid hormone (iPTH), calcium and phosphorus are considered to be associated with an increased risk of death. All these can be improved by treating SHPT [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].SHPT is mainly treated with pharmaceutical therapies and surgery, and microwave ablation also has a certain effect [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. The pharmaceutical therapies contain Vitamin D therapy, calcimimetics and phosphorus binders. Those who are unresponsive to drugs should consider parathyroidectomy (PTX) [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. With the use of cinacalcet and paricalcitol, more patients are able to control PTH levels. However, the rate of PTX did not therefore show a long-term decline accompanied with these therapeutic progress and parathyroidectomy is still an important treatment for SHPT [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. About 38% of patients need PTX after 20 years\u0026rsquo; dialysis [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThere are three main approaches of PTX, namely subtotal parathyroidectomy (SPTX), total parathyroidectomy with autotransplantation (TPTX\u0026thinsp;+\u0026thinsp;AT) and total parathyroidectomy (TPTX), of which the former two are the most common [\u003cspan additionalcitationids=\"CR13\" citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Some scholars have also proposed other methods that are more conservative or more radical than these three traditional ones, depending on the goal of PTH control [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Which way is the best is still in controversy [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. SPTX is more common in Europe and the United States, while TPTX\u0026thinsp;+\u0026thinsp;AT is conducted more frequently in Asian countries, which may be attributed to the difference of renal transplantation rate [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eA meta-analysis published in 2019 concluded that there is no significant difference in recurrence rate, complication rate and mortality between TPTX\u0026thinsp;+\u0026thinsp;AT and SPTX [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Polina V Zmijewski et al [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e] found that TPTX\u0026thinsp;+\u0026thinsp;AT has the advantage of lower recurrence rate when compared with SPTX, but the incidence of long-term hypocalcemia was higher. The risk of permanent hypoparathyroidism after SPTX is relatively lower, while TPTX\u0026thinsp;+\u0026thinsp;AT has the advantage of avoiding another neck surgery [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].Due to the differences in sample size, follow-up time and measurement, previous studies on these two surgical methods did not reach a consensus. The effects of postoperative level of PTH and calcium on cardiovascular complications and mortality need to be further evaluated. The aim of our study is therefore to compare the efficacy and safety of SPTX and TPTX\u0026thinsp;+\u0026thinsp;AT in short and long time from multiple perspectives.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003eSubjects\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAfter the approval of the Review Board of the Second Affiliated Hospital of Soochow University, we collected the data of patients diagnosed as SHPT and undergoing parathyroidectomy from January 1, 2010 to January 31, 2021. The inclusion criteria included: ESRD patients on hemodialysis or peritoneal dialysis; diagnosed as SHPT by symptoms, signs, and serologic and imaging examination; operative approach was TPTX+AT or SPTX; all relating data were complete. We excluded those who had received renal transplantation before PTX. Finally, a total of 259 patients were included in this study. Before operation, all patients or their relatives signed informed consent forms to participate in the study. All procedures were in accordance with the relevant guidelines and regulations.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePerioperative procedure\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIndications for PTX included persistently elevated iPTH level \u0026gt;800 pg/ml for more than 6 months that pharmaceutical therapies became ineffective, or there were significant symptoms\u0026nbsp;[1, 20, 21]. All patients were examined with parathyroid ultrasound and 99mTc-sestamibi radionuclide scan (Fig. 1). Serum iPTH, calcium and phosphorus were routinely evaluated before operation and in the early morning of the first day after operation. In TPTX+AT, all parathyroid glands were removed, and part of one approximately normal parathyroid was sliced into pieces at size of 1mm\u003csup\u003e3\u003c/sup\u003e, then 12~20 pieces were evenly transplanted in brachioradialis muscle in which side dialysis fistula was not located. Or parathyroid tissue can be directly made into homogenate and injected into deltoid muscle through syringe (Fig. 2). In SPTX, we retained about 50mg of the smallest parathyroid gland with all the remaining glands removed. Routine neck ultrasonography usually helps find thyroid lesions accidentally. Taking the complexity of reoperation on neck into consideration, we aggressively performed unilateral or bilateral thyroidectomy for those who are at great risk of thyroid cancer, with lymph node dissection carried out when necessary.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAfter handling all parathyroid glands, intraoperative iPTH level and frozen pathological examination were used in most patients in order to improve the success rate of the operation. If the level of intraoperative iPTH failed to drop below 50% of the preoperative level, we would search for the residual parathyroid gland, then examine iPTH again.\u003c/p\u003e\n\u003cp\u003eAll patients were treated with large doses of oral calcium, vitamin D3 or calcitriol, and intravenous calcium gluconate to prevent severe hypocalcemia, which was defined as serum calcium less than 1.6 mmol/L in any examination postoperatively. Serum calcium and phosphorus level were monitored every 6 hours within 24 hours after surgery. The frequency of monitoring and the dose of calcium supplement were adjusted according to the calcium level. When serum calcium When serum calcium rose to \u0026gt;1.9 mmol/L, with no symptoms of hypocalcemia like numbness and limb cramp, intravenous calcium was stopped to given. Patients on hemodialysis underwent dialysis on the day before and after surgery, while patients on peritoneal dialysis continued to dialysis on the night of surgery. Changes of patients\u0026rsquo; symptoms were evaluated within 7 days after operation. Perioperative complications, such as cervical hematoma, recurrent laryngeal nerve injury and infection, were recorded. Most patients were discharged after cervical drainage tube was removed and serum calcium reached a stable level. A few patients left hospital before that and immediately went to their dialysis center for further treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll patients enrolled in the study were given a phone call for follow-up, which was conducted by the same doctor. The follow-up was accomplished with the assistance of patients and/or their close relatives who had a full comprehension of their own condition. We collected data of all-cause mortality, recurrence, reoperation, adverse cardiovascular outcomes, and the corresponding time. We also recorded other complications such as fracture and permanent hypoparathyroidism, the relapse of common symptoms, and indicators which can reflect the economic burden of patients, including long-term pharmaceutical therapies and renal transplantation. Since some patients\u0026rsquo; dialysis center were not in our hospital, results of their postoperative serological examination cannot be directly obtained. For those who lack objective data, we got the missing data from the call. In our study, adverse cardiovascular outcomes were defined as angina pectoris, myocardial infarction, stroke, aneurysm rupture, and limb ischemia. We defined persistent SHPT as elevated iPTH \u0026gt;300pg/ml in any monitoring within 7 days after operation, and recurrent SHPT as iPTH increased \u0026gt;300pg/ml again during follow-up after a successful decrease postoperatively. It should be noted that the definitions of persistent and recurrent disease vary between literatures\u0026nbsp;[13, 20-24].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSPSS 23.0 and GraphPad Prism 5.01 were used for statistical analysis. Continuous variables are shown with means and standard deviations if they approximately conform to normal distribution, otherwise they are displayed by medians and interquartile ranges. Categorical variables are presented in numbers and percentages. Independent samples \u003cem\u003et\u003c/em\u003e test, chi-square test, Fisher\u0026rsquo;s exact test and Wilcoxon signed rank test were used to compare differences between the two groups depending on the type of variables when appropriate. Binary logistic regression analysis was used to look for risk factors for persistent SHPT. Kaplan-Meier method was utilized to show the incidence of all-cause death, recurrent SHPT, recurrent PTX (re-PTX) and adverse cardiovascular outcomes, and the differences between two groups were analyzed by stratified log-rank test. Risk factors for all-cause mortality and recurrent SHPT were evaluated by Cox-proportional hazard regression model. Covariates included gender, age, combined chronic diseases including hypertension, diabetes and coronary heart disease (others were not included because of the low quantity), level of preoperative serological examination, surgical method, number of parathyroid glands identified in operation and pathological results. P value was calculated by Wald test. Univariate Cox regression analysis was carried out for each covariate, then those with P\u0026lt;.05 were further enrolled into the multivariate analysis to determine the final risk factors. In all analyses, P\u0026lt;0.05 was considered statistically significant.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eBaseline characteristics of the SPTX and TPTX+AT groups\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere was no statistical difference in gender, age, serum calcium and phosphorus level, common symptoms (orthopedic pain, pruritus, obvious fatigue) and combined chronic diseases (hypertension, diabetes, coronary heart disease, stroke) between the SPTX and TPTX+AT groups (all P\u0026gt;.05). Preoperative serum iPTH and ALP level was higher in SPTX group than that in TPTX+AT group (P\u0026lt;.05). Due to the change of the preference of our medical team, no patient underwent SPTX in this study(P\u0026lt;.05) (Table 1).\u003c/p\u003e\n\u003cp\u003eTable 1\u003c/p\u003e\n\u003cp\u003eSome baseline characteristics of patients undergoing parathyroidectomy\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003eTPTX+AT(n=208)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003eSPTX(n=51)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eFemale sex\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e96 (46.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e28 (54.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.262\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eAge, y\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e50.3 (11.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e49.0 (10.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.479\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eNumber of parathyroid glands found by ultrasound\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e3.04 (0.94)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e3.43 (0.70)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.006\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eNumber of hyperfunctional parathyroid glands found by MIBI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e3.14 (1.03)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e2.67 (1.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.004\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eOrthopedic pain\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.114\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eSevere\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e55 (26.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e18 (35.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Light\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e78 (37.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e20 (39.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003ePruritus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e148 (71.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e34 (66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.530\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eObvious fatigue\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e35 (16.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e7 (13.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.590\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eHypertension\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e159 (76.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e41 (80.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.530\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e20 (9.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e5 (9.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.967\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eCoronary heart disease\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e14 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e2 (3.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.673\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eStroke\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e7 (3.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.397\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eiPTH, pg/mL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e1577.4 (1152.9-2177.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e1835.5 (1275.4-2621.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.023\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eSerum calcium, mmol/L\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e2.53 (0.23)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e2.52 (0.23)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.934\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eSerum phosphorus, mmol/L\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e2.29 (0.47)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e2.31 (0.52)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e0.838\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eALP, U/L\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e254.5 (137.3-437.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e488.0 (193.0-825.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003eYear of parathyroidectomy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026le;2013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e11 (5.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e12 (23.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;2014-2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e72 (34.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e39 (76.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.63157894736842%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026ge;2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e125 (60.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.140350877192983%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eValues are numbers (percent), mean (standard deviation) or median (interquartile range).\u003c/p\u003e\n\u003cp\u003eTPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; MIBI：\u003csup\u003e99m\u003c/sup\u003eTc-sestamibi radionuclide scan; IQR: interquartile range; iPTH: intact parathyroid hormone; ALP: alkaline phosphatase.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurgical results of the SPTX and TPTX+AT groups\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe number of parathyroid glands identified during operation between the two groups had no statistical difference (P=.120). More patients in TPTX+AT group underwent thyroidectomy concurrently than SPTX group (P=.006). The operation time in TPTX+AT group was statistically longer than SPTX group (both P\u0026lt;.05). Additional thyroidectomy would increase operation time, as a result, when patients who underwent thyroidectomy were excluded, the difference in operation time became no longer statistically significant (TPTX+AT: 125.4\u0026plusmn;38.8min, SPTX: 117.0\u0026plusmn;27.4min, P=.096). There are more patients diagnosed as parathyroid adenoma in TPTX+AT group than SPTX group (P\u0026lt;.05).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eShort-term efficacy and complications of the SPTX and TPTX+AT groups\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOn postoperative day 1 (POD1), the levels of serum iPTH, calcium and phosphorus decreased significantly compared with those before operation (all P\u0026lt;.05). The level of iPTH was significantly higher than that in TPTX+AT group (P=.023). The POD1 serum calcium level is higher in TPTX+AT group than that in SPTX group (P=.012), however, this difference was not statistically significant by 7 days after operation (P=.355). The results of laboratory examination on POD7 were lacked because they were discharged at that time. The rate of persistent SHPT in SPTX group is statistically higher than that in TPTX+AT group (P=.020). Further binary logistic regression analysis showed that high level of preoperative ALP (OR 1.002, 95% CI 1.000-1.004, P=.036) and small number of parathyroid glands identified during operation (OR 0.046, 95% CI 0.006-0.379, P=.004) were the risk factors for persistent disease. In terms of complications, severe hypocalcemia (TPTX+AT: 23.6%, SPTX: 19.6%, P=.547) was the most common. The incidence of cervical hematoma, wound infection and recurrent laryngeal nerve injury was very low, and there was no statistical difference between the two groups (all P\u0026gt;.05). No patient died during postoperative inpatient period. One patient who underwent TPTX+AT had blockage of lower limb dialysis fistula, resulting in local and systemic infection. The postoperative inpatient days was longer in SPTX group (P\u0026lt;.001) (Table 2). Common symptoms of most patients were improved after operation, and no statistical difference was found between the two groups (all P\u0026lt;.05) (Table 3).\u003c/p\u003e\n\u003cp\u003eTable 2\u003c/p\u003e\n\u003cp\u003ePerioperative information of patients undergoing parathyroidectomy\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003eTPTX+AT(n=208)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003eSPTX(n=51)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eOperation time, min\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e128.3 (38.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e116.2 (27.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.010\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eNumber of parathyroid glands identified\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e3.93 (0.38)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e3.80 (0.53)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.120\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eThyroidectomy performed concurrently\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e47 (22.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e3 (5.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.006\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePathological result\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.041\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Hyperplasia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e205 (98.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e47 (92.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Adenoma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e3 (1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e4 (7.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eDiagnosed as thyroid carcinoma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e14 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.119\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePOD1 iPTH, mmol/L\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e9.7 (5.4-24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e37.1 (7.0-121.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.023\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePOD1 calcium, mmol/L\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e1.91 (0.28)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e1.81 (0.23)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.012\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePOD1 phosphorus, mmol/L\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e1.83 (0.53)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e1.84 (0.53)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.913\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePOD7 calcium, mmol/L (n=180)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e1.86 (0.25)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e1.90 (0.19)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.355\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePOD7 phosphorus, mmol/L (n=180)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e1.13 (0.38)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e1.18 (0.53)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.581\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePersistent SHPT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e4 (1.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e5 (9.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.020\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eSevere hypocalcemia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e49 (23.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e10 (19.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.547\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eHematoma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e2 (1.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e1 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.484\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eRecurrent laryngeal nerve injury\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e1 (0.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e1 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.356\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eWound infection\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePostoperative inpatient days, d\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e7.32 (5.20)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e10.29 (5.83)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eValues are numbers (percent) or mean (standard deviation).\u003c/p\u003e\n\u003cp\u003ePTX: parathyroidectomy; TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; IQR:interquartile range; iPTH: intact parathyroid hormone; POD: postoperative day; SHPT: secondary hyperparathyroidism.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 3\u003c/p\u003e\n\u003cp\u003eChanges of common symptoms in patients undergoing parathyroidectomy\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" valign=\"top\" width=\"25.789473684210527%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.56140350877193%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.666666666666668%\"\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"42.98245614035088%\"\u003e\n \u003cp\u003ePostoperative\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" valign=\"top\" width=\"25.789473684210527%\"\u003e\n \u003cp\u003eSymptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" width=\"14.56140350877193%\"\u003e\n \u003cp\u003eGroup\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" width=\"16.666666666666668%\"\u003e\n \u003cp\u003ePreoperative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.789473684210526%\"\u003e\n \u003cp\u003eCompletely improved\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.035087719298245%\"\u003e\n \u003cp\u003ePartly improved\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"13.157894736842104%\"\u003e\n \u003cp\u003eBarely changed\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" width=\"15.114235500878735%\"\u003e\n \u003cp\u003eOrthopedic pain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" width=\"10.54481546572935%\"\u003e\n \u003cp\u003eSevere\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.586994727592268%\"\u003e\n \u003cp\u003eTPTX+AT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.695957820738137%\"\u003e\n \u003cp\u003e55 (26.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.817223198594025%\"\u003e\n \u003cp\u003e43 (78.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.0597539543058%\"\u003e\n \u003cp\u003e8 (14.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"13.181019332161688%\"\u003e\n \u003cp\u003e4 (7.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"19.62174940898345%\"\u003e\n \u003cp\u003eSPTX*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.458628841607567%\"\u003e\n \u003cp\u003e18 (35.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.27659574468085%\"\u003e\n \u003cp\u003e12 (66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.912529550827422%\"\u003e\n \u003cp\u003e5 (27.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.73049645390071%\"\u003e\n \u003cp\u003e1 (5.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" width=\"12.422360248447205%\"\u003e\n \u003cp\u003eLight\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.184265010351968%\"\u003e\n \u003cp\u003eTPTX+AT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.66873706004141%\"\u003e\n \u003cp\u003e78 (37.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.633540372670808%\"\u003e\n \u003cp\u003e61 (78.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.563146997929607%\"\u003e\n \u003cp\u003e6 (7.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.527950310559007%\"\u003e\n \u003cp\u003e11 (14.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"19.62174940898345%\"\u003e\n \u003cp\u003eSPTX*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.458628841607567%\"\u003e\n \u003cp\u003e20 (30.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.27659574468085%\"\u003e\n \u003cp\u003e14 (70.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.912529550827422%\"\u003e\n \u003cp\u003e2 (10.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.73049645390071%\"\u003e\n \u003cp\u003e4 (20.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" width=\"25.789473684210527%\"\u003e\n \u003cp\u003ePruritus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.56140350877193%\"\u003e\n \u003cp\u003eTPTX+AT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.666666666666668%\"\u003e\n \u003cp\u003e148 (71.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.789473684210526%\"\u003e\n \u003cp\u003e85 (57.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.035087719298245%\"\u003e\n \u003cp\u003e31 (20.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"13.157894736842104%\"\u003e\n \u003cp\u003e32 (21.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"19.62174940898345%\"\u003e\n \u003cp\u003eSPTX*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.458628841607567%\"\u003e\n \u003cp\u003e34 (66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.27659574468085%\"\u003e\n \u003cp\u003e21 (61.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.912529550827422%\"\u003e\n \u003cp\u003e8 (23.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.73049645390071%\"\u003e\n \u003cp\u003e5 (14.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"2\" width=\"25.789473684210527%\"\u003e\n \u003cp\u003eObvious fatigue\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.56140350877193%\"\u003e\n \u003cp\u003eTPTX+AT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.666666666666668%\"\u003e\n \u003cp\u003e35 (16.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.789473684210526%\"\u003e\n \u003cp\u003e13 (37.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.035087719298245%\"\u003e\n \u003cp\u003e10 (28.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"13.157894736842104%\"\u003e\n \u003cp\u003e12 (34.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"19.62174940898345%\"\u003e\n \u003cp\u003eSPTX*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.458628841607567%\"\u003e\n \u003cp\u003e7 (13.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.27659574468085%\"\u003e\n \u003cp\u003e5 (71.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.912529550827422%\"\u003e\n \u003cp\u003e1 (14.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.73049645390071%\"\u003e\n \u003cp\u003e1 (14.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eValues are numbers (percent).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e*P\u0026gt;.05 compared with TPTX+AT group postoperativelly\u003c/p\u003e\n\u003cp\u003eTPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up results and long-term outcomes of the SPTX and TPTX+AT groups\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAfter follow-up of all patients included in this study, we excluded 45 patients who were missed follow-up due to telephone change, inability to connect, reluctance to collaborate, and unclear memory. The remaining 204 patients included 165 in TPTX+AT group and 39 in SPTX group. The all-cause mortality in SPTX group is significantly higher than that in TPTX+AT group (P\u0026lt;.001). The causes of death included heart failure (4 cases), electrolyte disorder (4 cases), intracerebral hemorrhage (3 cases), malignant tumor (2 cases), myocardial infarction (1 case), infection (1 case) and accident (1 case). Recurrent SHPT happened in 29.7% of patients in SPTX group and 12.3% of patients in TPTX+AT group (P=.013). But conversely, re-PTX was less common in SPTX group (2.6%) than that in TPTX+AT group (9.1%), though not statistically significant (P=.302). There was no statistical difference between the two groups in complications like adverse cardiovascular outcomes, fracture, hypercalcemia, and permanent hypoparathyroidism. The two groups were similar in symptom deterioration, renal transplantation, and long-term pharmacal therapies (all P\u0026gt;.05) (Table 4, 5). Kaplan-Meier are shown in Fig. 3. Log rank test indicated TPTX+AT group has lower risk in all-cause death than SPTX group(P=.018), and re-PTX was more common in TPTX+AT group than that in SPTX group (P=.011). However, there was no statistical difference in recurrence and adverse cardiovascular outcomes between the two groups (both P\u0026gt;.05).\u003c/p\u003e\n\u003cp\u003eTable 4\u003c/p\u003e\n\u003cp\u003eLong-term outcomes of patients undergoing parathyroidectomy\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003eTPTX+AT(n=165)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003eSPTX(n=39)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003eAll-cause mortality\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e7 (4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e9 (23.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003eRecurrent SHPT*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e20 (12.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e11 (29.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.013\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003eRe-PTX\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e15 (9.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e1 (2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.302\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003eAdverse cardiovascular outcomes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e11 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e4 (10.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.666\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003eFracture\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e3 (1.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e2 (5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.244\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003ePrevalent hypercalcemia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e13 (7.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e2 (5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.802\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003ePermanent hypoparathyroidism\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e9 (5.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.290\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003eOrthopedic pain worsened\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e8 (4.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e2 (5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003ePruritus worsened\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e7 (4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.412\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.73204903677758%\"\u003e\n \u003cp\u003eRenal transplantation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.642732049036777%\"\u003e\n \u003cp\u003e2 (1.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.513134851138354%\"\u003e\n \u003cp\u003e1 (2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.112084063047284%\"\u003e\n \u003cp\u003e0.473\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e*Persistent SHPT were excluded.\u003c/p\u003e\n\u003cp\u003eValues are numbers (percent).\u003c/p\u003e\n\u003cp\u003eTPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; SHPT: secondary hyperparathyroidism; Re-PTX: recurrent parathyroidectomy.\u003c/p\u003e\n\u003cp\u003eTable 5\u003c/p\u003e\n\u003cp\u003eLong-term pharmaceutical therapies of patients undergoing parathyroidectomy\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003eTPTX+AT(n=165)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003eSPTX(n=39)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003ePvalue\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eCinacalcet\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e17 (10.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e2 (5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.488\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eCalcium\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e60 (36.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e10 (25.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.205\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eVitamin D\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e53 (32.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e9 (23.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.269\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003eCalcitriol\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e46 (27.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e6 (15.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.107\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"42.45614035087719%\"\u003e\n \u003cp\u003ePhosphorus binders\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"23.68421052631579%\"\u003e\n \u003cp\u003e54 (32.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.54385964912281%\"\u003e\n \u003cp\u003e15 (38.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.31578947368421%\"\u003e\n \u003cp\u003e0.496\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eRisk factors for all-cause death and recurrent SHPT\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCox regression analysis was performed for all-cause death and recurrent SHPT, and the covariate stroke was not included for the number was too small. In individual variable Cox regression analysis, the SPTX operation approach, older age, lower level of preoperative serum phosphorus was found to be associated with all-cause death after operation (all P\u0026lt;.05). However, after multiple Cox regression analysis, only the SPTX operation approach (HR 3.53, 95%CI 1.12-10.32, P=.021) and older age (HR 1.06, 95%CI 1.00-1.12, P=.035) were considered as risk factors for all-cause death (Table 6). No risk factor for recurrent SHPT was found in individual variable Cox regression analysis (all P\u0026gt;.05).\u003c/p\u003e\n\u003cp\u003eTable 6\u003c/p\u003e\n\u003cp\u003eRisk factors for all-cause death based on Cox regression analysis\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" valign=\"top\" width=\"49.73637961335677%\"\u003e\n \u003cp\u003eVariables\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.46572934973638%\"\u003e\n \u003cp\u003eHazard Ratio\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.332161687170476%\"\u003e\n \u003cp\u003e95% CI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.46572934973638%\"\u003e\n \u003cp\u003ePvalue\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"5\" valign=\"top\" width=\"100%\"\u003e\n \u003cp\u003e\u003cem\u003eStep 1: Individual variable analysis\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eOperative approach\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eTPTX+AT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"50.175438596491226%\"\u003e\n \u003cp\u003eComparison\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eSPTX\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e3.29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e1.17-9.25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.024\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eAge at operation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e1.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e1.01-1.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.018\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eHypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"50.175438596491226%\"\u003e\n \u003cp\u003eComparison\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e3.67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e0.48-27.77\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.209\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eDiabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"50.175438596491226%\"\u003e\n \u003cp\u003eComparison\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e3.47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e0.92-13.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.064\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eCoronary heart disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"50.175438596491226%\"\u003e\n \u003cp\u003eComparison\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e2.25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e0.50-10.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.288\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003ePreoperative iPTH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e1.00-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.880\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003ePreoperative serum calcium\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e1.39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e0.15-12.82\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.772\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003ePreoperative serum phosphorus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e0.10-0.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.045\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003ePreoperative ALP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e1.00-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.060\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eNumber of parathyroid glands identified\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e1.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e0.35-3.69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.839\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003ePathological result\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eHyperplasia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"50.175438596491226%\"\u003e\n \u003cp\u003eComparison\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eAdenoma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"5\" valign=\"top\" width=\"100%\"\u003e\n \u003cp\u003e\u003cem\u003eStep 2: Multiple analysis\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eOperative approach\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eTPTX+AT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"50.175438596491226%\"\u003e\n \u003cp\u003eComparison\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003cp\u003eSPTX\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e3.53\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e1.21-10.32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.021\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003eAge at operation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e1.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e1.00-1.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.035\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"32.80701754385965%\"\u003e\n \u003cp\u003ePreoperative serum phosphorus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"17.017543859649123%\"\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"19.29824561403509%\"\u003e\n \u003cp\u003e0.21-1.70\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"15.43859649122807%\"\u003e\n \u003cp\u003e0.338\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eCI: confidence interval; TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; iPTH: intact parathyroid hormone; ALP: alkaline phosphatase.\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this retrospective study of parathyroidectomy, we evaluated two surgical approaches from both short-term and long-term perspectives, and nearly 80% of patients completed follow-up. We found that although TPTX\u0026thinsp;+\u0026thinsp;AT seemed to be more effective in treating SHPT than SPTX within a short period after operation, there was no significant difference between these two surgical methods in the recurrence after a long time. The proportion of re-PTX was higher in patients after TPTX\u0026thinsp;+\u0026thinsp;AT than after SPTX. The incidence of complications in the two groups was similar. Nevertheless, the all-cause mortality of SPTX group was significantly higher than that of TPTX\u0026thinsp;+\u0026thinsp;AT group (23.1% and 4.2% respectively). Heart failure is the main cause of death in both groups.\u003c/p\u003e \u003cp\u003eTPTX\u0026thinsp;+\u0026thinsp;AT and SPTX are the two most common surgical treatments for SHPT, which can substantially improve patients\u0026rsquo; symptoms and reduce mortality [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Which is the best surgical method is still controversial. Moreover, PTX is not without risk [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Our results showed that these two surgical approaches are both of great benefit to SHPT patients. Most patients could completely or partially improve their postoperative symptoms, and could show a significant decrease in the level of serum iPTH, calcium and phosphorus. However, binary logistic regression analysis showed that the small number of parathyroid glands detected during operation was a risk factor for permanent SHPT, while the surgical method was not, suggesting that the occurrence of permanent SHPT may be attributed to the failure to detect all parathyroid glands during operation, rather than a specific surgical approach. Severe hypocalcemia was happened more commonly in TPTX\u0026thinsp;+\u0026thinsp;AT group than in SPTX group. Although the difference was not statistically significant, it indicated some potential risks may existed.\u003c/p\u003e \u003cp\u003eIn this study, recurrent SHPT occurred in about 15% of the patients. We found that recurrent SHPT was not related to the surgical method. It should be noted that the rate of permanent hypoparathyroidism in TPTX\u0026thinsp;+\u0026thinsp;AT group was higher than that in SPTX group (5.5% vs 0%), although there was no statistical difference. These patients are being treated with calcium, vitamin D or calcitriol continuously. Some of them have had to be hospitalized for intravenous calcium supplement, which may increase the economic burden and nursing cost, but as far as we know, no serious event happened due to hypocalcemia. The KDIGO guideline also believes mild and asymptomatic hypocalcemia to be harmless [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Besides, only about 10% of patients need to take cinacalcet to inhibit the continuous increase of PTH after PTX, which means surgery can reduce the treatment cost of most patients.\u003c/p\u003e \u003cp\u003eThe proportion of re-PTX was higher in TPTX\u0026thinsp;+\u0026thinsp;AT group than that in SPTX group, which probably be closely correlated with the mode of reoperation, in that most reoperation after TPTX\u0026thinsp;+\u0026thinsp;AT could be carried out inpatient or outpatient under local anesthesia. However, in patients undergoing SPTX, the degradation of systemic organ function led by ESRD may make them unable to tolerate another general anesthesia operation a few years after the original operation. In addition, the acceptability of patients should be taken into account in the selection of surgical approach.\u003c/p\u003e \u003cp\u003eElin Isaksson et al conducted a retrospective analysis of 824 patients in Sweden who underwent SPTX or TPTX (whether combined with AT was not distinguished), and concluded that SPTX had a lower risk of cardiovascular events but similar mortality when compared with TPTX\u0026thinsp;+\u0026thinsp;AT. They also suspected that the occurrence of cardiovascular events was associated with excessively low levels of iPTH after TPTX\u0026thinsp;+\u0026thinsp;AT [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Our study obtained different results. The incidence of adverse cardiovascular outcomes was lower in both groups, and there was no significant difference between the two groups, while the risk of death was significantly higher in the SPTX group. From these results, TPTX\u0026thinsp;+\u0026thinsp;AT seems to be a safer approach. However, the major cause of mortality of our patients is heart failure, which is also the main cause of death of ESRD. Since ESRD, and the combined hypertension or diabetes can also induce cardiovascular diseases by multiple mechanisms [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e], the relationship between operative methods and death still needs further study. Meanwhile, considering that only few patients (3/204) underwent renal transplantation after PTX, which is much lower than that study (273/804), it could possibly be reasons for the different results.\u003c/p\u003e \u003cp\u003eWe found that recurrent SHPT was not related to the surgical method. It should be noted that although the rate of permanent hypoparathyroidism in TPTX\u0026thinsp;+\u0026thinsp;AT group was higher than that in SPTX group (5.5% vs 0%), although there was no statistical difference. These patients are being treated with calcium, vitamin D or calcitriol continuously. Some of them have had to be hospitalized for intravenous calcium supplement, which may increase the economic burden and nursing cost, but as far as we know, no serious event happened due to hypocalcemia. The KDIGO guideline also believes mild and asymptomatic hypocalcemia to be harmless [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Besides, only about 10% of patients need to take cinacalcet to inhibit the continuous increase of PTH after PTX, which means surgery can reduce the treatment cost of most patients.\u003c/p\u003e \u003cp\u003eGenerally speaking, three and a half parathyroid glands are resected in SPTX, and TPTX\u0026thinsp;+\u0026thinsp;AT removes all parathyroid glands and then takes part of the tissue for autologous transplantation [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. However, there are differences in detail. For instance, parathyroid autotransplantation can be occurred in sites like sternocleidomastoid muscle, subcutaneous abdominal adipose tissue, brachioradialis muscle, deltoid muscle and anterior tibial muscle [\u003cspan additionalcitationids=\"CR29 CR30 CR31\" citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. In this study, the way of AT mainly depended on the preferences of surgeons, and was not distinguished.\u003c/p\u003e \u003cp\u003eIn recent years, more scholars have recommended TPTX alone for patients who have no hope of renal transplantation, and confirmed its safety and effectiveness, while TPTX\u0026thinsp;+\u0026thinsp;AT is still more recommended [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Out of concern about the complications of TPTX alone, our center has not widely carried out this approach.\u003c/p\u003e \u003cp\u003eThis study has some limitations. First, it is a retrospective study, lack of randomness. Second, there is imbalance in the follow-up time between the two groups. Though we have eliminated some of the effects through survival analysis, some information might still be missed. Third, the evaluation of patients' subjective feelings was mainly obtained by oral way, and no specific scale was used, which could lead to a certain bias.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eTPTX\u0026thinsp;+\u0026thinsp;AT and SPTX are both effective surgical approaches for the treatment of SHPT. Effectiveness and complication rates of them are similar. Considering the potential lower mortality risk of TPTX\u0026thinsp;+\u0026thinsp;AT and the quite low renal transplantation rate in Chinese population, we prefer TPTX\u0026thinsp;+\u0026thinsp;AT to treat SHPT patients in most Chinese population.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eSHPT: secondary hyperparathyroidism; ESRD: end-stage renal disease; PTH: parathyroid hormone; iPTH: intact parathyroid hormone; PTX: parathyroidectomy; TPTX+AT: total parathyroidectomy with autotransplantation; SPTX: subtotal parathyroidectomy; re-PTX: recurrent PTX; POD: postoperative day;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was approved by the Review Board of the Second Affiliated Hospital of Soochow University. All patients or their relatives signed informed consent forms to participate in the study. This study only collected the clinical data of patients and did not interfere with the treatment plan of patients. All patients\u0026rsquo; privacy has been well protected.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and/or analysed during the current study are not publicly available due the data collection process of this study took a large amount of time but are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was supported by the preponderant clinic discipline lifting project funding of the Second Affiliated Hospital of Soochow University (XKTJ-XK202009). This was also partly supported by grants from maternal and child health research project of Jiangsu Province (F202036). The funder of XKTJ-XK202009 was mainly responsible for publication charges. The funder of F202036 was Zhixue Yang who participated in the design of the study, monitored its implement and was responsible for part of publication charges.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eZJQ interpreted the patient data of perioperative period, and was a major contributor in writing the manuscript. WY carried out follow-up and interpreted the corresponding data, and was a contributor in writing the manuscript. HT was responsible for statistical analysis. JGQ and YZX participated in the design of the study, and YZX monitored its implement and revised the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe are deeply appreciative of the participants in this study and thank all staffs for their support and assistance.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e1\u0026nbsp;\u003c/sup\u003eDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e2\u0026nbsp;\u003c/sup\u003eDepartment of Emergency, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eLau WL, Obi Y, Kalantar-Zadeh K: Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clinical journal of the American Society of Nephrology: CJASN 2018, 13(6):952\u0026ndash;961.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFilho WA, van der Plas WY, Brescia MDG, Nascimento CP, Jr., Goldenstein PT, Neto LMM, Arap SS, Custodio MR, Bueno RO, Moyses RMA et al: Quality of life after surgery in secondary hyperparathyroidism, comparing subtotal parathyroidectomy with total parathyroidectomy with immediate parathyroid autograft: Prospective randomized trial. Surgery 2018, 164(5):978\u0026ndash;985.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLevy AR, Xing S, Brunelli SM, Cooper K, Finkelstein FO, Germain MJ, Kimel M, Platt RW, Belozeroff V: Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study. American journal of kidney diseases: the official journal of the National Kidney Foundation 2020, 75(3):373\u0026ndash;383.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDemeure MJ, McGee DC, Wilkes W, Duh QY, Clark OH: Results of surgical treatment for hyperparathyroidism associated with renal disease. American journal of surgery 1990, 160(4):337\u0026ndash;340.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKonturek A, Barczyński M, Stopa M, Nowak W: Subtotal parathyroidectomy for secondary renal hyperparathyroidism: a 20-year surgical outcome study. Langenbeck's archives of surgery 2016, 401(7):965\u0026ndash;974.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlock GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology: JASN 2004, 15(8):2208\u0026ndash;2218.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDiao Z, Liu X, Qian L, Liu J, Liu S, Liu W: Efficacy and its predictor in microwave ablation for severe secondary hyperparathyroidism in patients undergoing haemodialysis. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2016, 32(6):614\u0026ndash;622.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhao J, Qian L, Teng C, Yu M, Liu F, Liu Y, Tan X, Li J: A short-term non-randomized controlled study of ultrasound-guided microwave ablation and parathyroidectomy for secondary hyperparathyroidism. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2021, 38(1):1558\u0026ndash;1565.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCozzolino M, Elli F, Carugo S, Ciceri P: Secondary Hyperparathyroidism in End-Stage Renal Disease: No Longer a Matter for Surgeons? Blood purification 2016, 42(1):44\u0026ndash;48.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM: Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. Clinical journal of the American Society of Nephrology: CJASN 2016, 11(7):1260\u0026ndash;1267.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eK/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 2003, 42(4 Suppl 3):S1-201.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAnderson K, Jr., Ruel E, Adam MA, Thomas S, Youngwirth L, Stang MT, Scheri RP, Roman SA, Sosa JA: Subtotal vs. total parathyroidectomy with autotransplantation for patients with renal hyperparathyroidism have similar outcomes. American journal of surgery 2017, 214(5):914\u0026ndash;919.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiang Y, Sun Y, Ren L, Qi XW, Li Y, Zhang F: Short-term efficacy of surgical treatment of secondary hyperparathyroidism. European review for medical and pharmacological sciences 2015, 19(20):3904\u0026ndash;3909.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePolistena A, Sanguinetti A, Lucchini R, Galasse S, Avenia S, Monacelli M, Johnson LB, Jeppsson B, Avenia N: Surgical treatment of secondary hyperparathyroidism in elderly patients: an institutional experience. Aging clinical and experimental research 2017, 29(Suppl 1):23\u0026ndash;28.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShan CX, Qiu NC, Zha SL, Liu ME, Wang Q, Zhu PP, Du ZP, Xia CY, Qiu M, Zhang W: A novel surgical strategy for secondary hyperparathyroidism: Purge parathyroidectomy. International journal of surgery (London, England) 2017, 43:112\u0026ndash;118.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVeyrat M, Fessi H, Haymann JP, Ronco P, Lacau St Guily J, P\u0026eacute;ri\u0026eacute; S: Conservative three-quarter versus subtotal seven-eighths parathyroidectomy in secondary hyperparathyroidism. European annals of otorhinolaryngology, head and neck diseases 2019, 136(2):63\u0026ndash;68.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu ME, Qiu NC, Zha SL, Du ZP, Wang YF, Wang Q, Chen Q, Cen XX, Jiang Y, Luo Q et al: To assess the effects of parathyroidectomy (TPTX versus TPTX + AT) for Secondary Hyperparathyroidism in chronic renal failure: A Systematic Review and Meta-Analysis. International journal of surgery (London, England) 2017, 44:353\u0026ndash;362.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYuan Q, Liao Y, Zhou R, Liu J, Tang J, Wu G: Subtotal parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: an updated systematic review and meta-analysis. Langenbeck's archives of surgery 2019, 404(6):669\u0026ndash;679.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan der Plas W, Kruijff S, Sidhu SB, Delbridge LW, Sywak MS, Engelsman AF: Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease. Surgery 2021, 169(2):275\u0026ndash;281.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZmijewski PV, Staloff JA, Wozniak MJ, Mazzaglia PJ: Subtotal Parathyroidectomy vs Total Parathyroidectomy with Autotransplantation for Secondary Hyperparathyroidism in Dialysis Patients: Short- and Long-Term Outcomes. Journal of the American College of Surgeons 2019, 228(6):831\u0026ndash;838.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi JG, Xiao ZS, Hu XJ, Li Y, Zhang X, Zhang SZ, Shan AQ: Total parathyroidectomy with forearm auto-transplantation improves the quality of life and reduces the recurrence of secondary hyperparathyroidism in chronic kidney disease patients. Medicine 2017, 96(49):e9050.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchlosser K, Bartsch DK, Diener MK, Seiler CM, Bruckner T, Nies C, Meyer M, Neudecker J, Goretzki PE, Glockzin G et al: Total Parathyroidectomy With Routine Thymectomy and Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism: Results of a Nonconfirmatory Multicenter Prospective Randomized Controlled Pilot Trial. Annals of surgery 2016, 264(5):745\u0026ndash;753.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChoi HR, Aboueisha MA, Attia AS, Omar M, A EL, Toraih EA, Shama M, Chung WY, Jeong JJ, Kandil E: Outcomes of Subtotal Parathyroidectomy Versus Total Parathyroidectomy With Autotransplantation for Tertiary Hyperparathyroidism: Multi-institutional Study. Annals of surgery 2021, 274(4):674\u0026ndash;679.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim MS, Kim GH, Lee CH, Park JS, Lee JY, Tae K: Surgical Outcomes of Subtotal Parathyroidectomy for Renal Hyperparathyroidism. Clinical and experimental otorhinolaryngology 2020, 13(2):173\u0026ndash;178.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKetteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND et al: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney international 2017, 92(1):26\u0026ndash;36.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIsaksson E, Ivarsson K, Akaberi S, Muth A, Pr\u0026uuml;tz KG, Clyne N, Sterner G, Almquist M: Total versus subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery 2019, 165(1):142\u0026ndash;150.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A: Cardiovascular disease in dialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2018, 33(suppl_3):iii28-iii34.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCasella C, Galani A, Totaro L, Ministrini S, Lai S, Dimko M, Portolani N: Total Parathyroidectomy with Subcutaneous Parathyroid Forearm Autotransplantation in the Treatment of Secondary Hyperparathyroidism: A Single-Center Experience. International journal of endocrinology 2018, 2018:6065720.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIorio O, Petrozza V, De Gori A, Bononi M, Porta N, De Toma G, Cavallaro G: Parathyroid Autotransplantation During thyroid Surgery. Where we are? A Systematic Review on Indications and Results. Journal of investigative surgery: the official journal of the Academy of Surgical Research 2019, 32(7):594\u0026ndash;601.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTan CC, Cheah WK, Tan CT, Rauff A: Intramuscular injection of parathyroid autografts is a viable option after total parathyroidectomy. World journal of surgery 2010, 34(6):1332\u0026ndash;1336.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAnamaterou C, Lang M, Schimmack S, Rudofsky G, B\u0026uuml;chler MW, Schmitz-Winnenthal H: Autotransplantation of parathyroid grafts into the tibialis anterior muscle after parathyroidectomy: a novel autotransplantation site. BMC surgery 2015, 15:113.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSuwannasarn M, Jongjaroenprasert W, Chayangsu P, Suvikapakornkul R, Sriphrapradang C: Single measurement of intact parathyroid hormone after thyroidectomy can predict transient and permanent hypoparathyroidism: a prospective study. Asian journal of surgery 2017, 40(5):350\u0026ndash;356.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"efficacy, secondary hyperparathyroidism, total parathyroidectomy with autotransplantation, subtotal parathyroidectomy, end-stage renal disease","lastPublishedDoi":"10.21203/rs.3.rs-1363603/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1363603/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: No consensus has been reached on the best surgical approach for secondary hyperparathyroidism. We evaluated the short-term and long-term efficacy and safety of total parathyroidectomy with autotransplantation (TPTX+AT) and subtotal parathyroidectomy (SPTX).\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: We retrospectively analyzed the data of 259 patients undergoing TPTX+AT or SPTX between 2010 and 2021 in the Second Affiliated Hospital of Soochow University, and carried out follow-up. We compared the differences in symptoms, serological examinations, complications and mortalities between the two groups, and explored the risk factors of poor prognosis, death and recurrence.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e: Of the 259 patients, 208 underwent TPTX+AT and 51 underwent SPTX. The postoperative day 1 serum intact PTH level was higher in TPTX+AT group than that in SPTX group (P=.023). The risk of all-cause mortality in TPTX+AT group was lower (P =. 018), and recurrent PTX was more common in TPTX+AT group (P =. 011). The risk of recurrence was similar. There was no significant difference in the incidence of most complications including hematoma, recurrent laryngeal nerve injury, wound infection, adverse cardiovascular outcomes, fracture and permanent hypoparathyroidism between two groups. Results from Cox regression showed the SPTX operation approach (HR 3.53, P = 0.021) and older age (HR 1.06, P = 0.035) were risk factors of all-cause mortality.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e: Due to the lower risk of death after TPTX+AT and the low renal transplantation rate, we prefer TPTX+AT to treat most Chinese population with secondary hyperparathyroidism.\u003c/p\u003e","manuscriptTitle":"Efficacy and safety of total parathyroidectomy with autotransplantation vs. subtotal parathyroidectomy for secondary hyperparathyroidism: a retrospective study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-02-22 17:25:06","doi":"10.21203/rs.3.rs-1363603/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"9b0ceb1a-a5ab-4194-bbfa-1a186e10d8c5","owner":[],"postedDate":"February 22nd, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-03-14T05:44:15+00:00","versionOfRecord":[],"versionCreatedAt":"2022-02-22 17:25:06","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1363603","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1363603","identity":"rs-1363603","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}